Form D · Biotechnology
Ceapro Inc.
Edmonton, A0 · CIK 0001680765
Offering snapshot reported Jul 27, 2016 · SEC filing
- Reported sold
- $7.71M Offering amount: $7.71M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jul 13, 2016 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jul 27, 2016 | Initial | $7,713,074 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $2.86K
- Finders' fees
- $0
- Form D file number
- 021-267804
The above amounts are in US dollars and based on the noon CAD-USD conversion rate of July 13, 2016.
The above amounts are in US dollars and based on the noon CAD-USD conversion rate of July 13, 2016.
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| Echelon Wealth Partners Inc. | None |
Source: Form D, filed Jul 27, 2016. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Gilles Gagnon | Director, Executive |
| Ulrich Kosciessa | Director |
| William Li | Director |
| Donald Oborowsky | Director |
| Stacy Prefontaine | Executive |
| Glenn Rourke | Director |
| John Zupancic | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
7824 51 Avenue
Edmonton, A0, T6E 6W2
Edmonton, A0, T6E 6W2